Cell Therapeutics and Novartis Co-Develop Poliglumex Paclitaxel
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on September 19, 2006
When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.
Preclinical studies suggest that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels. Since the drug is trapped within the tumor, these cells are exposed to a significantly higher dose of chemotherapy compared to when standard paclitaxel is used.
More on the financial details of the agreement from CTI's press reelase.
Permalink: Cell Therapeutics and Novartis Co-Develop Poliglumex Paclitaxel
Tags:
cancer
paclitaxel
lung+cancer
chemotherapy
biotech
cell+therapeutics
poliglumex+paclitaxel
therapeut
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/36653


Mr Wong
